2023 CTAD Poster
2023 CTAD Poster:
Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.
2023 CTAD Poster:
Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.
2023 ADPD Poster:
Binding of Soluble Amyloid Beta Oligomer Species to Human IPSC-derived Excitatory Neurons Assessed Using a Panel of AB Antibodies.
2023 AAIC Presentation:
Topline results of INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.
2023 CTAD Presentation:
INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble Aβ oligomers.
2023 CTAD Poster:
INTERCEPT-AD: ACU193 CSF pharmacokinetics in early Alzheimer’s disease.
2023 CTAD Poster:
Incorporating the Study Participant’s Voice into Early Development of ACU193 for Early Alzheimer’s Disease: A Qualitative Interview Study Following Participation in the INTERCEPT-AD Study.
2023 CTAD Poster:
ACU193-sAβO Complex Measurement in CSF: Additional Analyses Using a Sensitive Assay of Target Engagement for the sAβO-Selective Antibody ACU193 in INTERCEPT-AD.